lung cancer
Conditions
Interventions
A:valsartan
Sponsors
Ji'nan Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old, both male and female are Ok. 2. Pathologically proven lung cancer patients, who are at advanced stages or locally advanced stage or inoperable early stage 3. ECOG score 0-1. 4. Life expectancy is more than 3 months. 5. Full organ function: expected survival time > 3 months; 6. Adequate hematopoietic function and liver and kidney function: A. neutrophil count >= 1.5 x 10^9/L; B. White blood cell count >= 3 x10^9/L; C. Platelet count >= 80 x 10^9/L; D. Hemoglobin >= 90g/L; E. Creatinine <= 1.5 x ULN; F. Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) <=2.5x ULN (<=5 x ULN for liver metastases); H. Total bilirubin <= 1.5 x ULN (<=3 x ULN for liver metastases); I. Alkaline phosphatase <= 5 x ULN; 7.patients are planned to receive conventional fractionated thoracic radiotherapy (single irradiation dose 1.8-2.0Gy), and the planned irradiation dose was more than 45Gy 8. Sign the informed consent form
Exclusion criteria
Exclusion criteria: 1. Patients with resting blood pressure less than 110/60 mmhg 2. Inability to swallow ,or a condition that investigators judge to severely impair gastrointestinal absorption (eg, chronic Diarrhea, intestinal obstruction, etc.). 3. Patients with severe pulmonary dysfunction disease, such as interstitial disease, severe chronic obstructive pulmonary disease (COPD), or thoracic radiotherapy is contraindicated 4.History of severe cardiovascular and cerebrovascular disease (hypertensive patients with stable blood pressure control may be admitted, but valsartan should be included in antihypertensive medication) 5. There are contraindications to oral valsartan, such as renal artery stenosis and severe renal impairment. 6. In the investigators' opinion , the patients are not eligible to participate in the study due to any clinical or laboratory abnormalities or other reasons 7. Previous thoracic radiotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of grade 2 or higher radiation pneumonitis within 3 months after radiotherapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety and tolerability of concomitant oral valsartan with thoracic radiotherapy; | — |
Countries
China
Contacts
Public ContactMeili Sun
Outcome results
None listed